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Atypical 
Chikungunya Virus 
Infections in 
Immuno-
compromised 
Patients 
To the Editor: Chikungunya fe-
ver was ﬁ  rst described in Tanganyika 
(now Tanzania) in 1952 and is now 
emerging in Southeast Asia. Chi-
kungunya virus (CHIKV) infection, 
a self-limiting febrile illness, shares 
similarities with dengue fever such 
as headache and myalgia. Addition-
ally, patients with CHIKV infection 
typically have arthralgia, arthritis, 
and tenosynovitis (1). Although usu-
ally benign, CHIKV infection may 
on rare occasions lead to neurologic 
and hepatic manifestations with high 
illness and mortality rates (2). We re-
port 2 immunocompromised patients 
with CHIKV infection associated with 
peritonitis, encephalitis, and second-
ary bacterial infections.
Patient A, a 66-year-old Singa-
porean-Chinese man, had a history 
of chronic renal disease secondary 
to obstructive uropathy. His baseline 
creatinine level was 300–400 μmol/L. 
For 3 years, he had ingested tradi-
tional Chinese medicine, which we 
suspect was contaminated by steroids 
because he appeared cushingoid. An 
outbreak of CHIKV infection was 
reported at his workplace. He was 
admitted to National University Hos-
pital, Singapore, in July 2008 with 
abdominal pain, vomiting, and fever 
of 1 day. He had no joint symptoms. 
Clinically, he had systemic inﬂ  amma-
tory response syndrome complicated 
by acute-on-chronic renal failure. His 
creatinine level was elevated at 921 
μmol/L on admission. A complete 
blood count showed leukocytosis 
(19.24 × 109 cells/L) with neutro-
philia and thrombocytopenia (62 × 
109 cells/L). Initial blood and urine 
cultures and serologic results were 
negative for dengue virus, but serum 
reverse transcription–PCR (RT-PCR) 
and indirect immunoﬂ  uorescent  as-
say for immunoglobulin G (IgG) 
(Euroimmun Medizinische Labor-
diagnostika, Lubeck, Germany) and 
IgM (CTK Biotech, Inc, San Diego, 
CA, USA) were positive for CHIKV 
(3,4). Computed tomographic scans 
of the abdomen showed dilated small 
bowel loops.
An urgent laparotomy did not 
show bowel perforation, but peritone-
al cultures yielded Klebsiella pneumo-
niae,  Escherichia coli, and Candida 
glabrata, and RT-PCR from the con-
centrated peritoneal ﬂ  uid was positive 
for CHIKV (3). He was administered 
appropriate antimicrobial drugs. He 
required repeat laparotomies because 
of elevated intraabdominal pres-
sure. He subsequently received broad 
spectrum antimicrobial drugs to treat 
secondary intraabdominal infections 
caused by P. aeruginosa and Entero-
coccus faecalis.
Ventilator-associated pneumonia 
also developed. Despite maximal sup-
port and prolonged antimicrobial ther-
apy, this patient died after 5 months of 
hospitalization.
Patient B, a 45-year-old Ma-
laysian–Chinese man with diabetes 
mellitus, had undergone a cadaveric 
liver transplant in 2001 for hepatitis 
B liver cirrhosis. He was receiving 
immunosuppressants (azathioprine 
and prednisolone). He was admitted 
in August 2008 after experiencing fe-
ver, headache, and abdominal bloat-
ing for 3 days. He had no neurologic 
symptoms. Acute self-limiting febrile 
illnesses with arthritis had occurred 
in his hometown; CHIKV infections 
were suspected.
Results of his examination on 
admission were normal, except for bi-
lateral enlarged cervical lymph nodes. 
Chest radiograph results were unre-
markable. He had mild transaminitis 
(alanine aminotransferase 173 U/L, 
aspartate aminotransferase 170 U/L), 
elevated C-reactive protein (107 
mg/L), and thrombocytopenia (120 
× 109 cells/L) without leukocytosis. 
Results of comprehensive serum and 
urine microbial studies were negative 
for posttransplant infections. Results 
of serum RT-PCR were negative for 
CHIKV, but IgG and IgM tests were 
positive for CHIKV.
Brain magnetic resonance im-
aging was performed because of the 
patient’s persistent severe headache 
and transient drowsiness. It showed 
several nonspeciﬁ  c areas of enhance-
ment, which suggested encephalitis, 
given the clinical scenario (Figure). 
However, a lumbar puncture was not 
performed, and hence, whether the 
patient’s cerebrospinal ﬂ  uid contained 
CHIKV could not be determined. 
Bilateral frontoparietal white mat-
ter lesions with restricted diffusion 
has been suggested as an early sign 
of viral encephalitis (5). However, a 
retrospective series demonstrated that, 
in CHIKV encephalitis, abnormalities 
on magnetic resonance imaging were 
uncommon, and no pathognomonic 
features were found (6).
Hospital-acquired pneumonia also 
developed and was treated with broad-
spectrum antimicrobial drugs. Bron-
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choscopic cultures were negative for 
CHIKV. The patient responded well 
to antimicrobial drugs, and his men-
tal status was normal on discharge. 
He possibly had encephalitis associ-
ated with CHIKV infection, compli-
cated by secondary hospital acquired 
pneumonia.
In this case, CHIKV was detected 
in peritoneal ﬂ  uid, but because of the 
positive bacterial cultures, we are not 
conﬁ  dent about its causative role in 
Patient A’s peritonitis. Although a 
series reported that 6 patients with 
CHIKV infection had perforated jeju-
nal diverticula while receiving long-
term nonsteroidal antiinﬂ  ammatory 
drugs and steroids (7), the perforations 
were likely secondary to prolonged ste-
roid use rather than CHIKV infection. 
In addition, both immunocompromised 
patients in our study had their CHIKV 
infections secondarily complicated by 
nosocomial infections. We note that 
other viral infections have been asso-
ciated with bacterial translocation and 
secondary nosocomial infections (8). 
Whether these infections were linked 
to CHIKV infection or to the underly-
ing chronic immunosuppressed state 
is unclear.
Both of our patients did not have 
the joint manifestations that are char-
acteristic of CHIKV infection (9). 
More prospective studies are required 
to determine the full spectrum of clini-
cal features of CHIKV infection in im-
munocompromised patients. Recently 
identiﬁ   ed biomarkers may predict 
patients at risk for complications but 
we were unable to study them in our 
patients (10). Although most cases of 
CHIKV infection are self-limiting, cli-
nicians should be alert to atypical pre-
sentations and severe complications in 
immunosuppressed patients.
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Lassa Fever, 
Nigeria, 2005–2008 
To the Editor: Lassa fever affects 
≈100,000 persons per year in West Af-
rica (1). The disease is caused by Las-
sa virus, an arenavirus, and is associ-
ated with bleeding and organ failure. 
The case-fatality rate in hospitalized 
patients is 10%–20%. The reservoir 
of the virus is multimammate mice 
(Mastomys natalensis). Investigations 
in the 1970s and 1980s pointed to the 
existence of 3 disease-endemic zones 
within Nigeria: the northeastern re-
gion around Lassa, the central region 
around Jos, and the southern region 
around Onitsha (2,3). The current 
epidemiologic situation is less clear 
because no surveillance system is in 
place. 
In 2003 and 2004, we conducted a 
hospital-based survey in Irrua, which 
demonstrated ongoing transmission 
of the virus in Edo State, Nigeria (4). 
Since then, laboratory capacity at the 
University of Lagos for diagnosing 
Lassa fever has been improved and 
used for small-scale passive surveil-
lance in other parts of the country. 
Public health ofﬁ   cials or hospital 
staff reported suspected cases. Blood 
samples were sent to Lagos, or staff 
from Lagos collected samples on site. 
Conﬁ  rmatory testing, sequencing, and 
virus isolation were performed at the 
Bernhard Nocht Institute for Tropi-
cal Medicine in Hamburg, Germany. 
Primary testing was done by reverse 
transcription–PCR (RT-PCR) that 
targeted the glycoprotein (GP) gene 
(5,6). An RT-PCR that targeted the 
large (L) gene was used as a second-
ary test (7), and PCR products were 
sequenced. Serologic testing for Lassa 
virus–speciﬁ  c  immunoglobulin  (Ig) 
G and IgM was performed by immu-
noﬂ  uorescent antibody test using Vero 
cells infected with Lassa virus. Virus 
isolation with Vero cells was conduct-
ed in the BioSafety Level 4 laboratory 
in Hamburg.
From 2005 through 2008, 10 cases 
of Lassa fever were conﬁ  rmed by vi-
rus detection (cases 3–10) or implicat-
ed by epidemiologic investigation and 
serologic testing (cases 1 and 2) (on-
line Appendix Table, www.cdc.gov/
EID/content/16/6/1040-appT.htm). 
Case-patients 1–4 were involved in 
a nosocomial outbreak that occurred 
in February 2005 at the Ebonyi State 
University Teaching Hospital (EB-
SUTH) in Abakaliki. Retrospective 
investigation suggests the following 
transmission chain. The presumed 
index case-patient was a male nurse 
living in Onitsha, who became ill on 
January 21, 2005, and traveled ≈200 
km to EBSUTH for better medical 
treatment. The detection of Lassa vi-
rus–speciﬁ  c IgM during his convales-
cent phase indicates that he had Lassa 
fever. The second case-patient was a 
female nurse who had contact with 
the index case-patient on February 4. 
She was admitted on February 7 and 
died 6 days later. Her clinical features 
were compatible with Lassa fever, but 
laboratory conﬁ  rmation is lacking be-
cause specimens were not collected. 
Two additional case-patients among 
hospital staff (case-patients 3 and 4) 
were seen on February 21; each had 
had contact with case-patient 2. Case-
patient 3 took care of case-patient 2 
and slept in the same room with her 
for 4 days. Lassa fever was conﬁ  rmed 
in case-patients 3 and 4 by RT-PCR 
as well as by IgM and IgG serocon-
version in the surviving patient (case-
patient 3). Case-patient 4, a pregnant 
nurse, had a spontaneous abortion and 
died on day 9 of hospitalization. Se-
quencing the GP and L gene PCR frag-
ments showed that case-patients 3 and 
4 were infected with the same virus 
strain (100% identity). In March and 
April 2005, blood was collected from 
50 hospital staff members (including 
those who had had contact with the 
case-patients) and screened for Lassa 
virus–speciﬁ  c IgM and IgG. No posi-
tive blood samples were found, which 
indicated that no additional staff mem-
bers were involved in the outbreak.
Case-patients 5 and 6 were admit-
ted to EBSUTH in 2008 on January 17 
and March 5, respectively. Both were 
medical doctors, one at a local hospi-
tal and the other at EBSUTH, and both 
died. Encephalopathy with general-
ized seizures and loss of conscious-
ness preceded death in both cases. 
The source of infection is unknown, 
although it is likely that they became 
infected while they treated patients 
without knowing they had Lassa fever. 
In agreement with the epidemiology, 
the viruses from the 2 patients were 
similar, though not identical (89% and 
87% identity in the GP and L genes, 
respectively).
Cases 7 to 10 occurred in Abuja 
and Jos from December 2007 through 
March 2008. Healthcare workers ap-
peared not to be involved, and no 
molecular epidemiologic evidence 
indicated that transmission occurred 
among the 3 case-patients from Jos 
(94–97% and 90–94% identity in the 
GP and L genes, respectively).
In conjunction with our previ-
ous report (4), the cases presented 
here demonstrate current Lassa fever 
activity in the states of Edo, Ebonyi, 
Federal Capital Territory, and Plateau. 
These ﬁ  ndings correspond to early re-
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